News & Events

News & Events

For media inquiries, please email cmayfield@homologymedicines.com

SIGN UP FOR NEWS ALERTS

News
& Events

Current News & Events | Archived News & Events

Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights

Homology Medicines to Participate in Upcoming Investor Conferences

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting

Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting

Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)

Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU

Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights

Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

Homology Medicines to Participate in Upcoming Investor Conferences

Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting

Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights

Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting

Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model

Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting

Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer

Homology Medicines Announces Pricing of Public Offering of Common Stock

Homology Medicines Announces Proposed Public Offering of Common Stock

Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

Rare Disease Day 2021: Recognizing the Superheroes Among Us

Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform

Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences

Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome

Homology Medicines Announces Publication in Life Science Leader

Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)